Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in the USA / NCT04326426
Enrolling by invitation Phase 3

ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection

NCT04326426 · tracked via the Priya Life Science USA tracker
Sponsor
Vanda Pharmaceuticals
Phase
Phase 3
Started
2020-04-13
Last updated
2020-04-20

Condition(s) studied

Coronavirus Infection

Investigational drug(s) / intervention(s)

Tradipitant →Placebo

Tradipitant: Neurokinin-1 antagonist

Placebo: Matching placebo

Study summary

This is a randomized, double-blind placebo-controlled trial to investigate the efficacy and safety of tradipitant 85 mg orally given twice daily to treat inflammatory lung injury associated with severe or critical COVID-19 infection.

On evaluation for enrollment, participant will need to meet all inclusion and exclusion criteria. If participant consents, they will be randomized 1:1 to treatment with either tradipitant 85 mg PO BID or placebo in addition to standard of care for COVID-19 infection as per the protocol at the treating hospital. NEWS 2 will be assessed at screening and daily following randomization. Inflammatory lab markers as detailed should be collected once per day in the morning, preferably at the same time every morning. All enrolled participants will have whole blood collected for whole genome sequencing.

Eligibility

Sex
ALL
Min age
18 Years
Max age
90 Years
Healthy volunteers
No
Inclusion Criteria: * Adults aged 18-90 * Confirmed laboratory COVID-19 infection by RT-PCR * Meeting severe or critical criteria of COVID-19 infection as defined at treating hospital * Confirmed pneumonia by chest radiograph or computed tomography * Fever defined as temperature ≥ 36.6 °C armpit, ≥ 37.2 °C oral, or ≥ 37.8 °C rectal * Oxygen saturation less than 92% Exclusion Criteria: * Recent use of illicit drugs or alcohol abuse * Known allergy to tradipitant or other neurokinin-1 antagonists * Pregnancy * Known HIV, HBV, or HCV infection * Malignant tumor, other serious systemic diseases * Inability to provide informed consent or to have an authorized relative or designated person provide informed consent, or to comply with the protocol requirements

Primary outcome measure(s)

  • Time to improvement on a 7-point ordinal scale as compared to baseline — 14 days or discharge

Trial sites (1)

FacilityCityRegionStatus
Lenox Hill Hospital Northwell Health New York New York

More Vanda Pharmaceuticals trials in the USA

Study to Evaluate the Efficacy and Safety of Ponesimod (VSP-128) in Patients With Moderately to Severely Active Ulcerative Colitis Recruiting
Development of Clinical Database of Individuals With Smith-Magenis Syndrome and Sleep Disturbances Recruiting
Randomized Withdrawal Study in Patients With Schizophrenia Recruiting
Evaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric Insomnia Recruiting
Safety and Tolerability of Open-Labeled Iloperidone in Adolescents Recruiting

Other trials for the same condition

SPI-1005 Treatment in Moderate COVID-19 Patients Enrolling by invitation
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04326426 on ClinicalTrials.gov ↗ ← All trials in the USA